A contact lens product having a cornea repair function includes a composition in the form of a solution. The composition includes gold nanoparticles and at least one auxiliary repairing ingredient. The gold nanoparticles are present in an effective concentration from 0.01 ppm to 3000 ppm and have an average particle size from 0.01 nm to 100 nm. The at least one auxiliary repairing ingredient is selected from the group consisting of chondroitin sulfate, α-lipoic acid, 2-aminoethanesulfonic acid, and potassium L-aspartate and present in an amount greater than 0 wt % and less than 20 wt % based on the composition being 100 wt %.

A nicotinamide adenine dinucleotide (NAD) precursor is provided for use in the treatment and/or prevention of an age-related medical condition in a subject. The NAD precursor is administered in combination with a calorie restriction diet (CRD) and/or a calorie restriction mimetic (CRM). Furthermore, a pharmaceutical combination is provided that includes a NAD precursor and a CRM.

A nicotinamide adenine dinucleotide (NAD) precursor is provided for use in the treatment and/or prevention of an age-related medical condition in a subject. The NAD precursor is administered in combination with a calorie restriction diet (CRD) and/or a calorie restriction mimetic (CRM). Furthermore, a pharmaceutical combination is provided that includes a NAD precursor and a CRM.

Methods of treating damaged bile ducts by way of elevating glutathione (GSH) levels, restoring normal GSH levels, and/or maintaining normal GSH levels in the biliary ducts are disclosed. A disclosed method comprises local treatment of damaged biliary ducts, e.g., by directly delivering to the bile ducts lumen of at least one active agent that promotes increasing of GSH production or inhibiting of GSH degradation in the biliary epithelial cells.

Methods of treating damaged bile ducts by way of elevating glutathione (GSH) levels, restoring normal GSH levels, and/or maintaining normal GSH levels in the biliary ducts are disclosed. A disclosed method comprises local treatment of damaged biliary ducts, e.g., by directly delivering to the bile ducts lumen of at least one active agent that promotes increasing of GSH production or inhibiting of GSH degradation in the biliary epithelial cells.

Methods of treating damaged bile ducts by way of elevating glutathione (GSH) levels, restoring normal GSH levels, and/or maintaining normal GSH levels in the biliary ducts are disclosed. A disclosed method comprises local treatment of damaged biliary ducts, e.g., by directly delivering to the bile ducts lumen of at least one active agent that promotes increasing of GSH production or inhibiting of GSH degradation in the biliary epithelial cells.

The present invention relates to solid oral compositions with controlled release of active ingredients, comprising a core consisting of a monolithic matrix comprising at least one low-, medium- or high-viscosity hydroxypropyl methylcellulose, or a mixture thereof, a hydroxypropyl cellulose (HPC) and one or more superdisintegrant polymers, and an outer coating of said core consisting of a layer comprising hydroxypropyl methylcellulose and/or ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

The present invention relates to solid oral compositions with controlled release of active ingredients, comprising a core consisting of a monolithic matrix comprising at least one low-, medium- or high-viscosity hydroxypropyl methylcellulose, or a mixture thereof, a hydroxypropyl cellulose (HPC) and one or more superdisintegrant polymers, and an outer coating of said core consisting of a layer comprising hydroxypropyl methylcellulose and/or ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

A method for providing a diagnosis and/or prognosis for a mitochondrial DNA (mtDNA) disorder or determining the risk of a mtDNA disorder developing in a subject, the method comprising the steps of assaying a stool sample from the subject to measure the level of mutated mtDNA molecules is provided. Methods for monitoring the progression of a mtDNA disorder, evaluating therapeutic effect of a treatment for a mtDNA disorder, and determining a subjects compliance with a prescribed treatment for a mtDNA disorder using a stool sample are also provided. Further, methods of treating a mtDNA disorder and uses of a stool sample in the methods described herein are also provided.

A method for providing a diagnosis and/or prognosis for a mitochondrial DNA (mtDNA) disorder or determining the risk of a mtDNA disorder developing in a subject, the method comprising the steps of assaying a stool sample from the subject to measure the level of mutated mtDNA molecules is provided. Methods for monitoring the progression of a mtDNA disorder, evaluating therapeutic effect of a treatment for a mtDNA disorder, and determining a subjects compliance with a prescribed treatment for a mtDNA disorder using a stool sample are also provided. Further, methods of treating a mtDNA disorder and uses of a stool sample in the methods described herein are also provided.